Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... InSound is honored by lat... Newark, CA (PRWEB) November 16, ...ic “invisible” hearing aid from InSoun...uo;s New Award in the Health category.  ...ic is designed to reside deep in the hearing canal...
(Date:11/18/2009)..., , DAVIS, Calif., Nov. 18 Ma...very, development and commercialization of effecti... products, announced that it has been named an IC2...tes, oldest and largest national angel investing g...erformance leading to rewarding results for all st...
(Date:11/18/2009)..., Security personnel need to be able to find ex...tact with them. To aid such searches, the National...h support from the Department of Homeland Security..., Standard Reference Material (SRM) 2905, Trace Pa...boratory assay methods, the SRM will be helpful in...
(Date:11/18/2009)... Scientists at Queen,s University Belfast are deve...llegal drugs which will help in the fight against ...ill use special gel pads to ,swipe, an individual ...alysed by a scanning instrument that can detect th...allow better, faster decisions to be made in respo...
Breaking Biology Technology:Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3Marrone Bio Innovations Named an IC20 Company 2New NIST trace explosives standard slated for homeland security duty 2New technology detects chemical weapons in seconds 2
...ration, ROCKVILLE, Md., Nov. 10 EntreMed, Inc.,(...ompany developing,therapeutics for the treatment o...d that it has met the primary endpoint for the eff... MKC-1 in combination with pemetrexed,(Alimta(R)) ...http://www.newscom.com/cgi-bin/prnh/20010620/ENMDL...
...wire/ -- Simcere Pharmaceutical,Group (NYSE: SCR ...generic,pharmaceuticals and innovative anti-cancer...et, announced today its participation in the Morga... conference will be held at,the Mandarin Oriental ...ef financial officer, Frank Zhigang Zhao, and vice...
... Center Dulles Airport Capital Partners will provi...tment opportunities. , Du...8 -- World Trade Center Dulles Airport Capital Par...es and investors seeking to access global markets,...Trade Centers Association General Assembly in Duba...
Other Biology Technology:EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 2EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 3Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2Former NASDAQ International President Among Execs Launching Firm to Access Global Markets 2Former NASDAQ International President Among Execs Launching Firm to Access Global Markets 3
(Date:11/20/2009)...report published in the November 2009 issue of the...cientists show how a family of genes (1-aminocyclo...responsible for production of ethylene. This gas a... information lays the foundation for future geneti...stant, able to survive and thrive in difficult ter...
(Date:11/20/2009)...recise measurements of plasma lipoprotein concentr...ectroscopy (NMR), researchers led by Daniel Chasma...cal School in Boston, MA, the Framingham Heart Stu...Stockholm, Sweden and Oxford, England performed ge... among 17,296 women of European ancestry from the ...
(Date:11/20/2009)...e invited to contribute their abstracts to the Wor...), the largest global meeting devoted to all aspec... patient care. The Congress will be held in Floren... abstracts can be submitted online at http://www....s February 4, 2010. , IOF and ESCEO are pleased ...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2Genetic analysis helps dissect molecular basis of cardiovascular disease 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Our brain looks at eyes first to identify a face 9280 1Our brain looks at eyes first to identify a face 9280 2Our brain looks at eyes first to identify a face 9280 3Invisibility cloak could protect against earthquakes 9278 1Invisibility cloak could protect against earthquakes 9278 2US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 52116 1US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 52116 2US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 52116 3US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 52116 4
...s display a dramatic reduction of cancer-causing g...ivate the expression of protective microRNAs in th...he June issue of Cancer Cell, demonstrates that ag...pact regulatory RNAs that may function as tumor su...ategy for treating human cancers. , DNA methylatio...
...sands of genes behave differently in the same orga...to this degree. Published in the August issue of ...same disease often strikes males and females diffe...y to the same drug. , "We previously had no good ...ionship to different diseases," explained Xia Yang...
...t females of many species face, and some may go to...om the June issue of the American Naturalist, Darr... from the University of Leeds suggest that female ...ives to avoid too much attention from males. Obser...of Trinidad, the researchers found that female gup...
Other Biology News:Activation of microRNA inhibits cancer gene in human cancer cells 2UCLA study finds same genes act differently in males and females 2UCLA study finds same genes act differently in males and females 3
Rabbit Anti-MAGE-D2 / NRAGE-Like 2b Polyclonal Antibody, Unconjugated from Upstate
Rabbit Anti-Rat 5-HIAA Polyclonal Antibody, Unconjugated from ImmunoStar, Inc.
NuParaffin Kit from Exalpha Biologicals, Inc.
Anti-hamster Ig HRP detection kit from BD Biosciences Pharmingen
Biology Products: